AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03553238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Karyotyping
Description: Karyotyping will be performed in PDT-ETP-ALL protocol.
Study NCT02275026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Description: Diffusion tensor imaging
Study NCT00486226 — intervention group
Intervention type: DEVICE
Intervention: Vascular Reconstruction Device
Description: CORDIS ENTERPRISE™ VRD
Study NCT02538146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine 1000mg 2X per day for 3 months
Description: non-essential dietary amino acid
Study NCT01819220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine/valsartan
Description: This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
Study NCT01819220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/telmisartan
Description: When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
Study NCT02940886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.
Study NCT02940886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
Study NCT02221297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement product with plant stanol ester
Description: 2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
Study NCT03237260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
Study NCT00502905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
Study NCT00502905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.
Study NCT03208192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transection during laparoscopic liver resection
Description: liver transection during laparoscopic liver resection
Study NCT00279903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Btx-A)
Description: Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
Study NCT00279903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: 1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
Study NCT00022711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
Study NCT02221297 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement product with plant stanol ester
Description: 2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
Study NCT01809990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy
Study NCT01818375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided
Study NCT01818375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard fluid therapy
Study NCT01254604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-Free Tafluprost or vehicle
Description: Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
Study NCT01254604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative-Free Timolol maleate
Description: Preservative-free timolol maleate (0.5%) ophthalmic solution
Study NCT02295930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: folfoxiri+cetuximab+surgery+cetuximab
Description: Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal.
Study NCT02295930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: folfoxiri+cetuximab+surgery+bevacizumab
Description: Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal.
Study NCT01210950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell and RPR injection
Description: mesenchymal cells and Plasma reach Protein are injected to the callus center
Study NCT01008930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HR PEM Scan
Description: PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
Study NCT01792986 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: water-only 24-hour fasting once per week for 6 weeks
Study NCT02158143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Study NCT00598533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin + Probucol-eluting stent (ISAR stent)
Description: due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
Study NCT00598533 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polymer based Zotarolimus-eluting stent (Endeavor Resolute)
Description: due to randomization, Zotarolimus-eluting stent with polymer will be implanted
Study NCT03378934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
Study NCT03378934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment for 12±1 weeks.
Study NCT04524936 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Study NCT03568006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific passive mobilization
Description: Specific passive mobilizations for the shoulder
Study NCT03378934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment for 12±1 weeks.
Study NCT03378934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.
Study NCT03378934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg once daily for 12±1 weeks.
Study NCT03568006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized treatment (standard protocol)
Description: Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
Study NCT03568006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized treatment (standard protocol)
Description: Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
Study NCT03648996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fructose diet, isocaloric
Description: 6 month of consumption a low fructose diet
Study NCT03648996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
Study NCT03648996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months of placebo treatment
Study NCT03648996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fructose, hypocaloric
Description: 6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
Study NCT03961919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine i.v. 30 mg/m²/d day -6 to -2
Study NCT03961919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: Cytarabine i.v. 2 g/m²/d day -6 to -2
Study NCT03961919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan i.v. 10 g/m²/d day -6 to -4
Study NCT03961919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant
Description: Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3
Study NCT03454048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (low dose)
Description: subcurative regimen (480 mg)
Study NCT03454048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine (high dose)
Description: Curative regimen (960mg)
Study NCT03454048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Curative regimen (1000mg/50mg)
Study NCT03454048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil
Description: Curative regimen (1000/400 mg, for 3 days)
Study NCT02841722 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)
Description: 8 additional blood samples
Study NCT03454048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum 3D7
Description: malaria challenge infection by P. falciparum 3D7-infected mosquito bites
Study NCT03454048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood stage malaria challenge infection, P. falciparum 3D7
Description: P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
Study NCT01713036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
Study NCT03378934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.
Study NCT03533478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral treatment Alzer y Diamel
Description: Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year.
Study NCT03533478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study NCT01278680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for walkstation usage
Description: The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
Study NCT01278680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives for walkstation usage
Description: The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
Study NCT01127425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic colonic resection
Description: Conventional surgery compared to laparoscopic sigmoid resection
Study NCT01127425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sigmoid resection
Description: sigmoid resection by laparoscopic surgery
Study NCT00813553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily
Study NCT00813553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Description: daily
Study NCT04644419 — intervention group
Intervention type: OTHER
Intervention: none (observational study)
Description: This is an observational study and does not include intervention delivery.
Study NCT02657252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Sclerotherapy of telangiectasis in one lower limb.
Study NCT02657252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol with Glucose
Description: Sclerotherapy of telangiectasis in one lower limb.
Study NCT00849693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
Study NCT00849693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
Study NCT00849693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
Study NCT00849693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
Study NCT00002735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: Cisplatin and 5-Fluorouracil
Study NCT00002735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
Study NCT00002735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
Study NCT02697955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: 50 mg bupivacaine and 50 μg adrenalin
Study NCT00002735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy
Description: 180 cGy per day, Days 1-5, every week for eight weeks
Study NCT02697955 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 mg sodium chloride pr. ml (0,9 %)
Study NCT03721081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1%/Epi 1:200000
Description: Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
Study NCT03721081 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Na Cl 0.9%/Epi 1:200000
Description: Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00459407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Undergo biopsy
Study NCT03378934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily for 12±1 weeks.
Study NCT02448173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OncoVAX and Surgery
Description: OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
Study NCT02448173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection of Stage II colon cancer
Study NCT02448173 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of Stage II colon cancer
Study NCT03855839 — intervention group
Intervention type: DEVICE
Intervention: Posture shirt
Description: Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
Study NCT03855839 — intervention group
Intervention type: DEVICE
Intervention: Compression shirt
Description: Compression shirts are designed for recreational sport activities and can be bought in any local sports store
Study NCT04269512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymph node dissection
Description: At least 10 lymph nodes must be removed.
Study NCT04655677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20-directed CAR-T cells
Description: Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Study NCT01816646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
Study NCT01816646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
Study NCT00973830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Guide and Brief Counseling
Description: If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).